8-K - bioAffinity Technologies, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

bioAffinity Technologies announced Q1 2026 CyPath® Lung unit sales exceeded internal projections with 146% year-over-year growth based on preliminary unaudited data.

Key Takeaways

1CyPath® Lung unit sales in Q1 2026 achieved 146% growth vs Q1 2025, exceeding internal projections.

2Reflects accelerating physician adoption and expanding clinical use of the noninvasive lung cancer diagnostic.

32025 audited results showed CyPath® Lung revenue up 87% YoY and units up 99% vs 2024.

4Addresses $3.58B U.S. market for pulmonary nodule management and lung cancer survivor surveillance.

5Real-world cases suggest potential to detect Stage 1A cancer and avoid unnecessary biopsies.

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

. Other Events.** On April 1, 2026, bioAffinity Technologies, Inc., a Delaware corporation, issued a press release announcing that unit sales for its CyPath® Lu

Other Event

9.01

. Financial Statements and Exhibits.** (d) Exhibits. | Exhibit Number | | Description | |---|---|---| | 99.1 | | Press Release issued by bioAffinity Technologie

Exhibits Only

Source Document

Results of Operations

First Quarter 2026

Metric	Value	Prior Period
CyPath® Lung Test Unit Sales Growth	146%	100%
CyPath® Lung Revenue Growth	87%	100%
CyPath® Lung Test Units Sold Growth	99%	100%

Exhibits (2)

8-K

99.1

EX-99.1